Suven Life Sciences completes Phase-1 trial of SUVN-I6107, advances to Phase-2

Business Updates View source PDF Explain this filing

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.3%Reaction day

₹270.20

prior close

₹260.70

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%-0.3% vs market

Healthcare Research Analytics & Technology peers, median of 5sector-0.2%+0.5% vs sector

On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.5 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.3

10m

+1.7

15m

+1.5

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.3+0.6-0.3-0.2+0.5

Next day

-1.9+1.7-3.6-1.1-0.8

-4.0+2.1-6.1-0.7-3.3

-1.0+3.0-3.9+1.4-2.4

-2.5+3.8-6.4+1.0-3.5

-4.4+3.1-7.5-1.5-2.9

-1.0+2.4-3.4-3.4+2.3

15d

+17.7+1.3+16.4-3.8+21.5

+26.2+3.9+22.3-0.7+26.9

+22.9+7.4+15.5+8.9+13.9

+23.8+5.6+18.2+9.0+14.8

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suven Life Sciences announced successful completion of the Phase-1 first-in-human study of SUVN-I6107, a novel muscarinic M1 positive allosteric modulator (M1-PAM) for cognitive disorders. The study in 64 healthy volunteers showed favorable safety, no serious adverse events, predictable pharmacokinetics, and biomarker evidence of CNS activity. The drug achieved projected therapeutic exposures with no gender-based dosing differences. This is the company's 5th internally discovered candidate to enter clinical development. SUVN-I6107 will now advance to Phase-2 evaluation. Suven owns full global IP rights.

Likely market impact

Positive pipeline milestone. Successful Phase-1 data de-risks the candidate and supports Phase-2 progression, strengthening long-term growth prospects.